Table of Content


List of Tables
List of Figures
Introduction
Global Markets Direct Report Coverage
Tourette Syndrome - Overview
Tourette Syndrome - Therapeutics Development
Pipeline Overview
Pipeline by Companies
Pipeline by Universities/Institutes
Products under Development by Companies
Products under Development by Universities/Institutes
Tourette Syndrome - Therapeutics Assessment
Assessment by Target
Assessment by Mechanism of Action
Assessment by Route of Administration
Assessment by Molecule Type
Tourette Syndrome - Companies Involved in Therapeutics Development
Asari Pharma AB
Catalyst Pharmaceuticals Inc
H. Lundbeck AS
KemPharm Inc
Neurocrine Biosciences Inc
SOM Biotech SL
Teva Pharmaceutical Industries Ltd
Therapix Biosciences Ltd
Tourette Syndrome - Drug Profiles
(amfetamine + guanfacine) - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
ABX-1431 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
alpha-dihydrotetrabezine - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
bevantolol - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
CPP-115 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
deutetrabezine - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
drobinol + palmidrol - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
ecopipam hydrochloride - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
sepranolone - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Small Molecule to Antagonize DRD2 for CNS Disorders and Hormol Disorders - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
THX-120 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
valbezine tosylate - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Tourette Syndrome - Dormant Projects
Tourette Syndrome - Discontinued Products
Tourette Syndrome - Product Development Milestones
Featured News & Press Releases
Aug 14, 2019: Emalex Biosciences announces first patient enrolled in phase 2b clinical study to evaluate the efficacy and safety of Ecopipam Tablets for the treatment of Pediatric Patients with Tourette Syndrome
Aug 06, 2019: Emalex Biosciences appoints Dr. Atul R. Mahableshwarkar as Senior Vice President of Drug Development
Dec 13, 2018: Neurocrine reports negative topline results from T-Force GOLD study
Oct 18, 2018: Abide Therapeutics starts Phase II trial of Tourette syndrome drug
Jun 11, 2018: Therapix Biosciences Sponsors the 2018 Annual Meeting of the European Society for the Study of Tourette Syndrome
Apr 10, 2018: Abide Therapeutics Presents Positive Data from a Phase 1b Study of ABX-1431 in Tourette Syndrome at the American Academy of Neurology 70th Annual Meeting
Apr 09, 2018: Therapix Biosciences Announces Topline Results of Phase IIa Study at Yale University for Tourette Syndrome Program
Feb 28, 2018: Nuvelution Pharma Announces Commencement of Patient Enrollment in Phase II/III Clinical Study of AUSTEDO? (deutetrabezine) for the Treatment of Tourette Syndrome in Pediatric Patients
Feb 07, 2018: Abide Therapeutics to Participate in February 2018 Investor Conferences
Feb 07, 2018: Therapix Biosciences Completes Pre-IND Communication With FDA on THX-110 for Tourette Syndrome: Clinical Development to Proceed as Projected
Dec 04, 2017: Therapix Biosciences Announces Completion of Enrollment of Phase IIa Study at Yale University for Tourette Syndrome Program
Nov 28, 2017: Abide Therapeutics Reports Positive Topline Data from Phase 1b Study of ABX-1431 in Tourette Syndrome
Oct 25, 2017: Neurocrine Initiates Phase IIb Clinical Study of Once-daily INGREZZA in Children and Adolescents with Tourette Syndrome
Oct 23, 2017: Neurocrine Granted FDA Orphan Drug Desigtion for Valbezine for the Treatment of Pediatric Patients With Tourette Syndrome
Oct 11, 2017: Nippon Chemiphar and SOM Biotech to Cooperate on New, Orphan Disease Indications for Bevantolol (Calvan)
Appendix
Methodology
Coverage
Secondary Research
Primary Research
Expert Panel Validation
Contact Us
Disclaimer



List of Figures


Number of Products under Development for Tourette Syndrome, H2 2019
Number of Products under Development by Companies, H2 2019
Number of Products by Top 10 Targets, H2 2019
Number of Products by Stage and Top 10 Targets, H2 2019
Number of Products by Top 10 Mechanism of Actions, H2 2019
Number of Products by Stage and Top 10 Mechanism of Actions, H2 2019
Number of Products by Routes of Administration, H2 2019
Number of Products by Stage and Routes of Administration, H2 2019
Number of Products by Stage and Molecule Types, H2 2019


List of Tables


Number of Products under Development for Tourette Syndrome, H2 2019
Number of Products under Development by Companies, H2 2019
Number of Products under Development by Universities/Institutes, H2 2019
Products under Development by Companies, H2 2019
Products under Development by Universities/Institutes, H2 2019
Number of Products by Stage and Target, H2 2019
Number of Products by Stage and Mechanism of Action, H2 2019
Number of Products by Stage and Route of Administration, H2 2019
Number of Products by Stage and Molecule Type, H2 2019
Tourette Syndrome - Pipeline by Asarina Pharma AB, H2 2019
Tourette Syndrome - Pipeline by Catalyst Pharmaceuticals Inc, H2 2019
Tourette Syndrome - Pipeline by H. Lundbeck AS, H2 2019
Tourette Syndrome - Pipeline by KemPharm Inc, H2 2019
Tourette Syndrome - Pipeline by Neurocrine Biosciences Inc, H2 2019
Tourette Syndrome - Pipeline by SOM Biotech SL, H2 2019
Tourette Syndrome - Pipeline by Teva Pharmaceutical Industries Ltd, H2 2019
Tourette Syndrome - Pipeline by Therapix Biosciences Ltd, H2 2019
Tourette Syndrome - Dormant Projects, H2 2019
Tourette Syndrome - Discontinued Products, H2 2019